Joseph Rubinfeld
Nessuna posizione attualmente
Storia della carriera di Joseph Rubinfeld
Precedenti posizioni note di Joseph Rubinfeld
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| LADRX CORPORATION | Direttore/Membro del Consiglio | 01/07/2002 | 26/12/2016 |
| Independent Dir/Board Member | 01/07/2002 | 26/12/2016 | |
| REGENICIN, INC. | Direttore/Membro del Consiglio | 25/08/2010 | 26/12/2016 |
| Independent Dir/Board Member | 24/08/2010 | 12/05/2014 | |
| AMARANTUS BIOSCIENCE HOLDINGS, INC. | Direttore/Membro del Consiglio | 05/12/2014 | 26/12/2016 |
| Independent Dir/Board Member | 05/12/2014 | 26/12/2016 | |
SuperGen, Inc.
 SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | Direttore/Membro del Consiglio | 08/02/2005 | 08/02/2005 |
| Direttore Tecnico/Scientifico/R&S | 08/02/2005 | 08/02/2005 | |
| Fondatore | 08/02/2005 | 08/02/2005 | |
| AMGEN INC. | Direttore operativo | 01/01/1983 | 01/01/1983 |
| Fondatore | 01/01/1983 | 01/01/1983 | |
| Cetus Corp. | Direttore/Membro del Consiglio | 01/01/1968 | 01/01/1980 |
Vivacitas Oncology, Inc.
 Vivacitas Oncology, Inc. Medical/Nursing ServicesHealth Services Vivacitas Oncology, Inc. is a private clinical stage biopharmaceutical company founded in 2015 by Dr. Joseph Rubinfeld and Infusion 51a, LP. The company is based in Walnut Creek, CA. Vivacitas Oncology is focused on combating cancers that have proven to be resistant to current treatment modalities. The company aims to improve upon well-known chemotherapies with demonstrated effect, but which also possess challenges with potency, toxicity, stability, and other issues limiting their use. The CEO is Mark J. Suseck. | Fondatore | 01/01/2015 | - |
Imcure Therapeutics, Inc.
 Imcure Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Imcure Therapeutics, Inc. provides biopharmaceutical products. The firm develops small molecule therapeutics to treat diseases. The company was founded by Joseph Rubinfeld in December 2003 and is headquartered in San Francisco, CA. | Fondatore | - | - |
| SAREPTA THERAPEUTICS, INC. | Direttore/Membro del Consiglio | - | - |
| ░░░░░░░░░░░░░░░░░ ░░░░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | - | - |
| ░░░░░░░░░░░░░░░ ░░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | - | - |
| ░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
Formazione di Joseph Rubinfeld
| The Trustees of Columbia University in The City of New York | Doctorate Degree |
| The City College of New York | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 15 |
Posizioni
| Director/Board Member | 7 |
| Founder | 4 |
| Independent Dir/Board Member | 3 |
Settori
| Health Technology | 11 |
| Consumer Services | 3 |
| Consumer Non-Durables | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 6 |
|---|---|
| AMGEN INC. | Health Technology |
| COLGATE-PALMOLIVE COMPANY | Consumer Non-Durables |
| LADRX CORPORATION | Health Technology |
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| REGENICIN, INC. | Health Technology |
| AMARANTUS BIOSCIENCE HOLDINGS, INC. | Health Technology |
| Aziende private | 6 |
|---|---|
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | Health Technology |
Imcure Therapeutics, Inc.
Imcure Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Imcure Therapeutics, Inc. provides biopharmaceutical products. The firm develops small molecule therapeutics to treat diseases. The company was founded by Joseph Rubinfeld in December 2003 and is headquartered in San Francisco, CA. | Health Technology |
Quark Pharmaceuticals, Inc.
 Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Health Technology |
| Cetus Corp. | Health Technology |
Vivacitas Oncology, Inc.
Vivacitas Oncology, Inc. Medical/Nursing ServicesHealth Services Vivacitas Oncology, Inc. is a private clinical stage biopharmaceutical company founded in 2015 by Dr. Joseph Rubinfeld and Infusion 51a, LP. The company is based in Walnut Creek, CA. Vivacitas Oncology is focused on combating cancers that have proven to be resistant to current treatment modalities. The company aims to improve upon well-known chemotherapies with demonstrated effect, but which also possess challenges with potency, toxicity, stability, and other issues limiting their use. The CEO is Mark J. Suseck. | Health Services |
- Borsa valori
- Insiders
- Joseph Rubinfeld
- Esperienza
